Literature DB >> 12525651

Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus.

Jörn E Schmitz1, Marcelo J Kuroda, Sampa Santra, Meredith A Simon, Michelle A Lifton, Wenyu Lin, Rajinder Khunkhun, Michael Piatak, Jeffrey D Lifson, Gudrun Grosschupff, Rebecca S Gelman, Paul Racz, Klara Tenner-Racz, Keith A Mansfield, Norman L Letvin, David C Montefiori, Keith A Reimann.   

Abstract

Cellular immune responses mediated by CD8+ lymphocytes exert efficient control of virus replication during primary simian immunodeficiency virus (SIV) infection. However, the role that antibodies may play in the early control of virus replication remains unclear. To evaluate how antibody responses may affect virus replication during primary SIVmac infection, we depleted rhesus monkeys of B cells with anti-CD20 antibody. In normal rhesus monkeys immunized with tetanus toxoid, anti-CD20 treatment and resulting depletion of B cells inhibited the generation of antitetanus antibodies, while tetanus-specific T-cell responses were preserved. During the first 4 weeks after inoculation with SIVmac251, development of SIV-specific neutralizing antibody was delayed, and titers were significantly lower in B-cell-depleted monkeys than control-antibody-treated monkeys. Despite the lower neutralizing antibody titers, the levels of plasma SIV RNA and the linear slope of the decline seen in B-cell-depleted monkeys did not differ from that observed in monkeys treated with control antibody. However, beginning at day 28 after SIV infection, the B-cell-depleted monkeys showed a significant inverse correlation between neutralizing antibody titers and plasma virus level. These results suggest that the rapid decline of peak viremia that typically occurs during the first 3 weeks of infection was not significantly affected by SIV-specific antibodies. However, the inverse correlation between neutralizing antibodies and plasma virus level during the postacute phases of infection suggests that humoral immune responses may contribute to the control of SIV replication.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12525651      PMCID: PMC140983          DOI: 10.1128/jvi.77.3.2165-2173.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

Review 1.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

Review 2.  Human immunodeficiency virus associated changes in germinal centers of lymph nodes and relevance to impaired B-cell function.

Authors:  K Tenner-Racz
Journal:  Lymphology       Date:  1988-03       Impact factor: 1.286

3.  The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection.

Authors:  J D Lifson; M A Nowak; S Goldstein; J L Rossio; A Kinter; G Vasquez; T A Wiltrout; C Brown; D Schneider; L Wahl; A L Lloyd; J Williams; W R Elkins; A S Fauci; V M Hirsch
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.

Authors:  J E Clements; R C Montelaro; M C Zink; A M Amedee; S Miller; A M Trichel; B Jagerski; D Hauer; L N Martin; R P Bohm
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

5.  Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile.

Authors:  N L Haigwood; A Watson; W F Sutton; J McClure; A Lewis; J Ranchalis; B Travis; G Voss; N L Letvin; S L Hu; V M Hirsch; P R Johnson
Journal:  Immunol Lett       Date:  1996-06       Impact factor: 3.685

6.  Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.

Authors:  C C Tsai; K E Follis; A Sabo; T W Beck; R F Grant; N Bischofberger; R E Benveniste; R Black
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

7.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

Authors:  M E Reff; K Carner; K S Chambers; P C Chinn; J E Leonard; R Raab; R A Newman; N Hanna; D R Anderson
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113

8.  In vivo administration to rhesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication.

Authors:  K A Reimann; L C Burkly; B Burrus; B C Waite; C I Lord; N L Letvin
Journal:  AIDS Res Hum Retroviruses       Date:  1993-03       Impact factor: 2.205

9.  Follicular dendritic cells retain HIV-1 particles on their plasma membrane, but are not productively infected in asymptomatic patients with follicular hyperplasia.

Authors:  J Schmitz; J van Lunzen; K Tenner-Racz; G Grossschupff; P Racz; H Schmitz; M Dietrich; F T Hufert
Journal:  J Immunol       Date:  1994-08-01       Impact factor: 5.422

10.  Inhibition of normal B-cell function by human immunodeficiency virus envelope glycoprotein, gp120.

Authors:  N Chirmule; N Oyaizu; V S Kalyanaraman; S Pahwa
Journal:  Blood       Date:  1992-03-01       Impact factor: 22.113

View more
  53 in total

1.  Antiviral antibodies are necessary for control of simian immunodeficiency virus replication.

Authors:  Christopher J Miller; Meritxell Genescà; Kristina Abel; David Montefiori; Donald Forthal; Kristen Bost; Jun Li; David Favre; Joseph M McCune
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

Review 2.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 3.  T-bet-expressing B cells during HIV and HCV infections.

Authors:  James J Knox; David E Kaplan; Michael R Betts
Journal:  Cell Immunol       Date:  2017-07-11       Impact factor: 4.868

4.  T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response.

Authors:  James J Knox; Marcus Buggert; Lela Kardava; Kelly E Seaton; Michael A Eller; David H Canaday; Merlin L Robb; Mario A Ostrowski; Steven G Deeks; Mark K Slifka; Georgia D Tomaras; Susan Moir; M Anthony Moody; Michael R Betts
Journal:  JCI Insight       Date:  2017-04-20

Review 5.  Role of Fc-mediated antibody function in protective immunity against HIV-1.

Authors:  George K Lewis
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

6.  Influence of disulfide-stabilized structure on the specificity of helper T-cell and antibody responses to HIV envelope glycoprotein gp120.

Authors:  Denise Mirano-Bascos; N Kalaya Steede; James E Robinson; Samuel J Landry
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

7.  Use of an anti-CD16 antibody for in vivo depletion of natural killer cells in rhesus macaques.

Authors:  Elisa I Choi; Rijian Wang; Lauren Peterson; Norman L Letvin; Keith A Reimann
Journal:  Immunology       Date:  2008-01-12       Impact factor: 7.397

8.  In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells.

Authors:  Joseph K Wong; Matthew C Strain; Rodin Porrata; Elizabeth Reay; Sumathi Sankaran-Walters; Caroline C Ignacio; Theresa Russell; Satish K Pillai; David J Looney; Satya Dandekar
Journal:  PLoS Pathog       Date:  2010-01-29       Impact factor: 6.823

9.  A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.

Authors:  Panagiotis Vagenas; Meropi Aravantinou; Vennansha G Williams; Edith Jasny; Michael Piatak; Jeffrey D Lifson; Andres M Salazar; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  PLoS One       Date:  2010-09-21       Impact factor: 3.240

10.  CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.

Authors:  Koen K A Van Rompay; Raman P Singh; Bapi Pahar; Donald L Sodora; Casey Wingfield; Jonathan R Lawson; Marta L Marthas; Norbert Bischofberger
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.